The Role of Peptide YY (PYY)in Inhibiting Food Intake.

What Was Tested

This registered not phased trial tested Peptide YY.

Measurements of appetite, ad libitum energy intake, blood pressure and blood sampling will be performed during the test day.

The registry classes the interventions as drug.

Who Took Part

The registry lists 24 planned participants were the target.

It was open to men only aged from 20 years up to 50 years.

Healthy volunteers could join, not only people with the condition.

Examples of who could join: Normal weight (BMI: 18-23 kg/m2) or 12 overweight/obese (BMI: 27-40 kg/m2). Body weight fluctuations \< 5 kg over the past 2 months. Blood pressure normal to mildly hypertensive(\<159/99 mm Hg). Non-elite athletes and not planning to change physical activity during the study.

The full record lists 4 inclusion and 8 exclusion criteria; among the exclusions: any physiological or psychological illnesses that could influence the study results; regular use of medicine; smoking defined as \<1 cigarette per day.

How the Study Was Run

It was run as a non-randomized, crossover and single-blind study.

In the crossover set-up each of the participants took both Peptide YY and the comparison in turn, acting as their own control.

Only one side, usually the participants, was kept unaware of whether Peptide YY was given.

It started in 2005-03 with completion listed for 2005-05.

Its stated primary purpose is treatment.

What Was Measured

Researchers chose this as the main measure: appetite. energy intake.

It also tracked 2 secondary outcomes, for example Plasma PYY profile and Blood pressure.

What This Means in Plain Language

Put simply, this is a not phased, non-randomized trial of Peptide YY in 24 people.

Its size is small, so on its own it can only give an early look.

The trial is marked completed; no results are posted to the registry yet, so nothing here describes outcomes.

More context: the Peptide YY compound page, all human trials.